Cannabis history & culture in Switzerland

From useful plant to narcotic — and back

Cannabis is one of the oldest cultivated plants of all. Archaeological finds document the use of hemp fibres and seeds for millennia in Central and East Asia, and medicinal applications are documented early on in Chinese and Indian sources. In Europe, hemp was a strategic raw material for centuries: ropes, canvas, paper, and textiles relied on it, and in Switzerland, too, hemp cultivation was a completely ordinary agricultural activity until the 20th century.

The break came in the 20th century and was international in nature. Through a series of international treaties — culminating in the Single Convention on Narcotic Drugs of 1961 — cannabis was integrated into the global narcotics control regime. Switzerland followed this development with the Narcotics Act, which criminalised cultivation, trade, and consumption, removing the plant from the legal economic cycle.

The third phase has been underway for around three decades and is partially reversing this trend: medical re-authorisation, decriminalisation of small quantities, regulated markets in individual states and — in Switzerland — the 1% rule for CBD as well as the scientifically monitored pilot trials.

• Antiquity to modern times: fibre, seeds, medicine — hemp as an everyday raw material
• 1961: Single Convention on Narcotic Drugs, international prohibition
• 1990s: Swiss hemp shop wave and its end
• Since 2011: 1% rule; since 2022 medical cannabis without a BAG exceptional permit

The Swiss special role

Switzerland is a special case in European cannabis history because it has repeatedly acted earlier and more pragmatically than its neighbours. In the 1990s, a broad hemp shop scene emerged, operating in a grey area for a decade before being largely shut down by coordinated law enforcement. In 2008, the electorate rejected the Hemp Initiative; at the same time, the four-pillar drug policy established itself as an internationally acclaimed approach that explicitly lists harm reduction as an independent goal.

2011 saw the raising of the THC limit to 1%, which made today's CBD market possible in the first place — significantly more generous than the 0.2 to 0.3% in most EU countries. Total THC is always the decisive factor, i.e. THC plus THCA multiplied by the factor 0.877. A product with 0.4% delta-9-THC and 0.9% THCA has around 1.19% total THC and is therefore a narcotic — even if the packaging says «under 1%».

In 2022, medical cannabis became prescribable without a BAG exceptional permit, and BetmG Art. 8b established the basis for pilot trials in several cities. The Cannabis Products Act (CanPG) currently under discussion would be the next step: from time-limited trials to a permanently regulated market.

What you will find in this cluster

The subpages go through the eras individually — ancient and medieval use, the industrialisation of the fibre, the history of prohibition in the 20th century, the Swiss hemp shop era, the four-pillar policy, and the current reform debate.

Anyone who wants to understand why today's legal situation seems so confusing will almost always find the explanation in the prohibition phase — most of today's rules are repairs to a system built for a different era.

The medical paradigm shift since August 2022

Until a few years ago, access to medical cannabis in Switzerland was associated with high bureaucratic hurdles. Patients required an exceptional licence from the Federal Office of Public Health (BAG), which often delayed supply. With the amendment of the law in August 2022, this requirement was abolished. Since then, the responsibility for prescribing lies entirely in the hands of the treating physicians. This change significantly facilitates therapeutic use, as prescriptions can now be dispensed directly through regular pharmacies, provided the preparations are approved by Swissmedic or manufactured as magistral formulations.

Despite this liberalisation, reimbursement by the mandatory health insurance (OKP) remains an unresolved issue in practice. Health insurance funds still decide on a case-by-case basis whether to fund the treatment, which represents a significant financial burden for many of those affected. In addition, as part of the accompanying research, physicians must submit anonymised treatment data to the BAG. In the long term, this data collection is intended to provide evidence-based insights into the efficacy and safety of medical cannabis in everyday Swiss practice and serve as a basis for future reimbursement rules.

• Abolition of the BAG exceptional licence simplifies access for pain and spasticity patients.
• Prescribing authority lies directly with the treating medical professionals.
• Dispensing is carried out in a controlled manner via specialised Swiss pharmacies.
• Mandatory data collection by the medical profession for scientific accompanying research.

Science instead of a grey area: The current pilot trials

Following the end of the unregulated hemp shop era, Swiss politicians sought new ways to categorise cannabis consumption from a social and health perspective. The answer to this is the time-limited pilot trials under Article 8b of the Narcotics Act. Projects such as Züri Can in Zurich, Weed Care in Basel, or SCRIPT in Bern and Lucerne are investigating the effects of regulated distribution under scientific supervision. The aim is to obtain sound data on consumption patterns, the mental health of participants, and the displacement of the black market in order to create a rational basis for future legislation.

The purchase of cannabis in these studies is strictly regulated and differs fundamentally from free markets. Participants must be of legal age, reside in the respective canton or municipality, and undergo regular surveys. Dispensing takes place via selected points of sale such as pharmacies, social clubs, or cantonal dispensing points. The products are subject to strict quality controls by the Federal Food Safety and Veterinary Office (BLV) and the BAG, thereby ruling out contamination. This controlled dispensing serves as a model for a potential future Cannabis Products Act.

• The legal basis is formed by the temporary Article 8b of the Narcotics Act.
• Scientific monitoring by universities and cantonal health departments.
• Dispensing of quality-tested cannabis exclusively to registered study participants.
• Focus on the protection of minors, prevention, and curbing the illegal trade.

Federalism in enforcement: Cantonal differences in fixed penalty fines

Although the Narcotics Act applies at the federal level, Swiss federalism is reflected in all its diversity when it comes to enforcement. A key example is the handling of small quantities for personal consumption. Adults found with an amount of under ten grams of THC cannabis must expect varying reactions from law enforcement authorities. While some cantons issue a fixed penalty fine of one hundred francs directly, others refrain from immediate penalisation under certain circumstances if no active consumption is proven. This inconsistency often leads to uncertainty among consumers regarding their rights.

Tolerance limits and the intensity of checks also vary greatly between urban areas and rural regions. In cities with ongoing pilot trials, awareness of the issue is often higher, whereas in more conservative cantons, enforcement and repression remain the focus. In practice, this means that travelers must be aware of the local interpretation of the federal law. The cantonal police forces use their discretionary power independently when enforcing the Narcotics Act, which leads to an asymmetric legal reality within Switzerland, even though the legal basis is uniform.

• Fixed penalty fine of one hundred francs for the consumption of THC cannabis by adults.
• Differing interpretation of the exemption from punishment for the mere possession of small quantities of under ten grams.
• Significant variations in the frequency of checks between urban centres and rural cantons.
• Local police regulations influence the practical implementation of federal law in everyday life.

The uncompromising practice in Swiss road traffic

A common and consequential mistake when dealing with cannabis in Switzerland concerns participation in road traffic. Unlike alcohol, a strict zero-tolerance practice applies to cannabis, which is defined by an extremely low detection limit in the blood. This limit is a mere 1.5 micrograms of tetrahydrocannabinol per litre of blood. Since THC and its metabolites are only slowly broken down by the body, detection even days after the last consumption can lead to being classified as unfit to drive. This affects not only recreational users, but explicitly also patients who use medical cannabis.

The consequences of a positive blood analysis are severe and range from the immediate revocation of the driving licence to heavy fines and mandatory traffic medical assessments. In the first instance, the authorities do not differentiate between whether there was acute impairment or whether consumption occurred long ago. Regular users risk the permanent loss of their driving aptitude due to suspected dependency. In case of uncertainty or overdose, Tox Info Suisse offers an initial medical point of contact via the emergency number 145, but cannot avert the legal consequences in road traffic.

• Strict zero-tolerance practice with a detection limit of 1.5 micrograms of THC per litre of blood.
• Unfitness to drive is legally presumed, regardless of the subjective perception of impairment.
• High risk of driving licence revocation, even for registered medical cannabis patients.
• Traffic medical assessments of driving aptitude are associated with substantial out-of-pocket costs.

FAQ